Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2014

View Archived Issues

Novel biomarkers of cardiovascular injury and disease presented at the ACC meeting

New NHE-1 inhibitor to prevent cardiovascular disease-related reperfusion injury

Hepatera begins pilot study of Myrcludex B in HDV

Defense Department grant funds gene therapy study for ALS

U.S. proof-of-concept study of Glassia begins in GVHD

Astellas submits MAA for Xtandi for chemotherapy-naive mCRPC

Adempas approved in the E.U. for two life-threatening forms of pulmonary hypertension

Regado Biosciences extends enrollment in phase III trial of REG-1

Allegro Diagnostics reports results from BronchoGen genomic test trial

MDxHealth and LI PATH enter into marketing agreement for ConfirmMDx

First patient enrolled in phase III trial of clonidine gel for diabetic neuropathy

Rosetta Genomics and Marina Biotech to develop microRNA products for rare diseases

Cepheid confirms launch of Xpert HPV, a rapid test for cervical cancer-related HPV

NICE recommends the exhaled nitric oxide testing to diagnose and manage asthma

Reata Pharmaceuticals reports discovery of NO production inhibitors

Qbtech launches FDA-cleared ADHD test

Mitsubishi Tanabe Pharma and Shanghai Pharmaceuticals jointly present novel renin inhibitors

Australian researchers report development of ICMT inhibitors

Eternity Bioscience prepares new B-raf inhibitors

Study of RO-5186582 enrolling subjects with Down syndrome

Gilead Sciences reports data from phase III study of sofosbuvir in HCV in Japan

Researchers identify potential biomarker of mitochondrial dysfunction in acute kidney injury

FDA clears IND for OMS-721 in thrombotic microangiopathies

Janssen begins phase III OPTIMIST trials of simeprevir in combination with sofosbuvir

Cytonet's liver cell therapy shows benefit in patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...